GERN
HEALTHCAREGeron Corporation
AI Insight
What's Moving GERN Today?
No stock-specific AI insight has been generated for GERN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.04$2.01
$1.35
Fundamentals
Market Cap$860M
P/E Ratio—
EPS$-0.11
Dividend Yield—
Dividend / Share—
ROE-27.1%
Profit Margin-34.3%
Debt / Equity—
Trading
Volume13.1M
Avg Volume (10D)—
Shares Outstanding641.5M
GERN News
21 articles- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 18, 2026
- Geron Corp stock (US3741631036): Focus on valuation as short interest easesAD HOC NEWS·Jun 5, 2026
- After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)Yahoo Finance·Jun 4, 2026
- Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·Jun 1, 2026
- Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·May 19, 2026
- First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026Yahoo Finance·May 12, 2026
- Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?Yahoo Finance·May 11, 2026
- A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 GuidanceYahoo Finance·May 8, 2026
- Geron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price TargetsYahoo Finance·May 8, 2026
- Geron Corporation Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Geron Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Geron (GERN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·May 6, 2026
- Geron Plans to Present at Upcoming Investor ConferencesYahoo Finance·May 5, 2026
- Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal OfficerYahoo Finance·Apr 25, 2026
- Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 22, 2026
- Geron Adds Chief Legal Officer As Equity Ties To Execution RiskYahoo Finance·Apr 15, 2026
- Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 14, 2026
- Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham ConfMarketbeat·Apr 14, 2026
- Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGlobeNewswire Inc.·Apr 13, 2026
- Geron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire Inc.·Apr 6, 2026
All 21 articles loaded
Price Data
Open$1.32
Previous Close$1.35
Day High$1.36
Day Low$1.29
52 Week High$2.01
52 Week Low$1.04
52-Week Range
$1.04$2.01
$1.35
Fundamentals
Market Cap$860M
P/E Ratio—
EPS$-0.11
Dividend Yield—
Dividend / Share—
ROE-27.1%
Profit Margin-34.3%
Debt / Equity—
Trading
Volume13.1M
Avg Volume (10D)—
Shares Outstanding641.5M
About Geron Corporation
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—